Impel NeuroPharma Revenue and Competitors
Estimated Revenue & Valuation
- Impel NeuroPharma's estimated annual revenue is currently $44.9M per year.
- Impel NeuroPharma received $67.5M in venture funding in December 2018.
- Impel NeuroPharma's estimated revenue per employee is $313,750
- Impel NeuroPharma's total funding is $211.3M.
Employee Data
- Impel NeuroPharma has 143 Employees.
- Impel NeuroPharma grew their employee count by -30% last year.
Impel NeuroPharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Commercial Operations & Analytics | Reveal Email/Phone |
2 | VP Clinical Development & Operation | Reveal Email/Phone |
3 | VP Sales | Reveal Email/Phone |
4 | Chief Technology & Development Officer | Reveal Email/Phone |
5 | Director, Life Sciences | Reveal Email/Phone |
6 | Chief Commercial Officer | Reveal Email/Phone |
7 | Senior Director, Market Access | Reveal Email/Phone |
8 | Senior Clinical Data Manager | Reveal Email/Phone |
9 | Sr. Clinical Trial Lead | Reveal Email/Phone |
10 | Neurology Sales Specialist | Reveal Email/Phone |
Impel NeuroPharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.9M | 39 | 117% | $14.9M | N/A |
#2 | $44.9M | 143 | -30% | $211.3M | N/A |
#3 | $54M | 172 | 11% | $35.5M | N/A |
#4 | $4.3M | 17 | -19% | N/A | N/A |
#5 | $18.3M | 73 | N/A | N/A | N/A |
#6 | $8.3M | 33 | 6% | N/A | N/A |
#7 | $81.1M | 323 | 17% | N/A | N/A |
#8 | $7M | 28 | -12% | N/A | N/A |
#9 | $204.8M | 816 | 3% | N/A | N/A |
#10 | $6.3M | 50 | 25% | $27.5M | N/A |
What Is Impel NeuroPharma?
Impel NeuroPharma, Inc., is a privately-held, Seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (CNS) diseases. Impel's products are based on a novel nasal drug delivery platform, the POD device, that administers drug to the upper nasal cavity in a consistent and predictable manner. Impel NeuroPharma is currently investigating INP104 (POD DHE) for acute migraine headache, INP103 (POD levodopa) for Parkinson's Disease, INP105 (POD olanzapine) for agitation in schizophrenia and bipolar disorders as well as INP102 (POD insulin) for Alzheimer's disease in an NIH funded trial. Impel NeuroPharma's proprietary POD device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. To learn more about Impel NeuroPharma, please visit our website at http://impelnp.com.
keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power
$211.3M
Total Funding
143
Number of Employees
$44.9M
Revenue (est)
-30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Impel NeuroPharma News
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing...
Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand.
SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $22M | 143 | -3% | N/A |
#2 | $38.9M | 144 | 7% | $17.2M |
#3 | N/A | 144 | 7% | N/A |
#4 | $52M | 144 | 7% | N/A |
#5 | $35.1M | 145 | 8% | $3M |
Impel NeuroPharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2013-11-29 | $2.6M | Undisclosed | Article | |
| 2015-10-15 | $12.0M | B | 3M New Ventures | Article |
| 2016-09-01 | $1.1M | Undisclosed | Article | |
| 2016-12-05 | $36.0M | C | venBIO | Article |
| 2018-12-07 | $67.5M | D | KKR | Article |